Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





FDA-Approved Cholesterol-Lowering Drug Could Reduce SARS-CoV-2’s Ability to Reproduce or Even Make it Disappear

By HospiMedica International staff writers
Posted on 15 Jul 2020
A FDA-approved cholesterol-lowering drug could stop SARS-CoV-2 from controlling our metabolism and potentially downgrade COVID-19’s danger level to that of a common cold.

Research by the Hebrew University of Jerusalem (Jerusalem, Israel) and Mount Sinai Medical Center (Miami, FL, USA) has revealed that the FDA-approved drug Fenofibrate (Tricor) could reduce SARS-CoV-2’s ability to reproduce or even make it disappear. More...
In a report by The Jerusalem Post, the researchers have explained that viruses are parasites and cannot replicate themselves or make new viruses, but need to enter a human cell and then hijack it. The research team which spent the last three months studying what SARS-CoC-2 is doing to human lung cells found that the novel coronavirus prevents the routine burning of carbohydrates, resulting in large amounts of fat accumulating inside lung cells - a condition required for the virus to reproduce.

The researchers believe that by understanding how the SARS-CoV-2 controls our metabolism, we can wrestle back control from the virus and deprive it from the very resources it needs to survive. A review of a panel of eight already approved drugs that could possibly interfere with the virus’s ability to reproduce revealed that Tricor caused the cells to start burning fat, resulting in the virus almost completely disappearing within only five days of treatment. According to the report, the experiment was conducted in lab studies both in Israel and New York and was replicated several times with different lung samples. The researchers are now advancing to animal studies in New York and hope to fast-track clinical studies in both Israel and the US within the next couple of weeks, as the drug is already proven to be safe.

Related Links:
Hebrew University of Jerusalem
Mount Sinai Medical Center



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Emergency Ventilator
Shangrila935
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.